Upcoming events in the life science industry
We are pleased to announce that the 17th Annual European Life Sciences CEO Forum (Sachs_ELSF) will take place on the 28th - 29th February 2024 back at the Hilton Zurich Airport Hotel. The event will be part of the Sachs Spring Life Sciences Week, which will also incorporate the 5th Annual European HealthTech CEO Forum. The success and longevity of the forum is built on the goodwill and repeat attendance of major corporate and financial investors, and pharma licensing executives and advisors, who are seeking to network with biotechs. The programme and presentations allow all to keep up with the latest industry developments and strategize for 2024. The physical programme will consist of the usual panels and keynotes, which will be available on demand from the 6th of March. Additionally, there will be pre-arranged in-person meetings, live and on demand company showcases and a reception. During the online week, virtual meetings will be available through the audio/video online meeting system. The main programme for the 17th Annual ELSF is spread throughout 2 days (28th - 29th of February) and will feature more than 12 hours of high-level keynotes and panel discussions. In addition, there will be a global company showcase of 50+ presentations by established public, private, emerging and seed companies, offering innovative solutions and seeking investment and partnering opportunities. This will include a limited number of live presentations taking place in dedicated presentation tracks, alongside virtual company showcases, which will be available on demand during the virtual week. We anticipate 400+ delegates will register for the forum from all Life Sciences sectors, with the target audience being corporate and financial investors/partners, banks and advisors with part of the audience participating virtually.
Biotechgate Digital Partnering is a virtual conference designed to support the business development of Biotech, Medtech and Pharma companies. Join five days of digital partnering and establish new global connections thanks to pre-arranged one-on-one Zoom meetings, along with informal networking events and workshops.
Swiss Nordic Bio in Zurich is a high-level partnering and investor event where Swiss and Nordic biotech and healthtech startups, pharmaceutical companies and investors meet. Swiss Nordic Bio carries 17 years of tradition, previously Swiss Scandinavian Bio-Business Seminar, and is organised by the Nordic countries in cooperation with Swiss partners. The conference has a broad focus within biotech, healthtech and pharma (drug development, drug delivery, bio materials, medical device, diagnostics, contract manufacturing, CRO, etc.) and gathers small, early stage companies as well as global, commercial corporations.
The eighteenth annual BIO-Europe Spring® conference is back in-person and will be taking place from 18 to 20 March 2024 in Barcelona, Spain Building and nurturing relationships is an essential part of the progression of successful business partnerships. BIO-Europe Spring 2024 will offer a fusion of innovative digital solutions and a vibrant on-site event of unprecedented scope. Expanding on the success of EBD Group’s flagship conference, BIO-Europe® , BIO-Europe Spring will bring together over 3,700 leading executives from around the world. Specifically, we will host more than 20,000 partnering meetings to connect leaders from academia, start-up, and scale-up biotech companies with forward-thinking investors and pharma companies. Along with world-class workshops and panels, innovative company presentations, active exhibition and a variety of networking opportunities make this event an unrivalled forum for companies across the biotech value chain to meet and do business.
The Redefining Early Stage Investments (RESI) conference series connects start-ups and early-stage investors and strategic channel partners. RESI maximizes fundraising companies’ efforts to find partners who are a fit for their technology and stage of development. RESI is uniquely cross-border and cross-domain, connecting start-ups with 10 categories of global investors across the silos of drugs, devices, diagnostics and digital health. RESI caters to both the earliest stage start-ups, those seeking grants, seed and angel capital, and the early-stage firms who seek series A and B funding. RESI is a unique and powerful tool for sourcing assets and advancing innovation across early-stage life science and healthcare.
A methodology for assessing the risk profile of a life science company prior to valuation. The different valuation methods used for life science companies and products. How to calculate the value of a biotech or life science company with the Discounted Cash Flow method, comparables and exit valuation. How to use risk-adjusted Net Present Value (rNPV) to calculate the value of a pharmaceutical compound in development. How to structure the licensing deal between companies, covering issues such as milestone and royalty payments.
The Swiss Biotech Day is a premier biotechnology conference in Europe, attracting professionals from the global life sciences community. In 2024, it will once again provide a platform for networking, engaging discussions, and the exploration of advancements in R&D, manufacturing, data management, artificial intelligence, and innovative financing. International biotech delegations use the “Global Village” to strengthen their ties with Switzerland as a biotech hub and promote cross-border investments, public-private partnerships, research and development collaborations and exchange of talent.
Asia Bio Partnering Forum will continue to build on its strong start and will gather biotech and pharma leaders from around the world with hundreds of emerging innovators across Asia Pacific to advance dealmaking in Asia. Asia Bio Partnering Forum will bring together over 500 innovators from key Asian markets with life science leaders from around the world to advance dealmaking across Asia. Meet one-to-one with innovative companies across Asia. Leverage informal networking opportunities to expand your network. Access the largest network of cross-border partners to accelerate your global partnering strategies. Find your partner of choice at the event’s active exhibit. This event presents a valuable opportunity to refine and broaden your partnering strategies across Asia. Don’t miss out to delve into the dynamic environment of one of the fastest-growing and most productive hubs for biotech and deal-making.
The 10th LSX World Congress is the leading partnering, strategy and investment event in Europe, with qualified 1:1 partnering at its core. The event brings together the CEOs and senior decision makers from the world's most innovative biopharma, medtech and healthtech companies with investors, senior BD&L teams, R&D leaders and industry KOLs. Together, they share best practice, forge partnerships and investments - all geared at putting capital and ideas to work to help create the world's future medicines and improve patient outcomes.
Since 2006, BIO KOREA has been holding the International Convention every year for invigorating and growing the global bio-health industry. This year also, we are pleased to announce the 19th BIO KOREA will be held on May 8-10, 2024 at COEX, Seoul. Through various programs of BIO KOREA 2024 including Business Partnering, Exhibition, Conference, and Invest Fair, exchange the newest bio-health trends and technology as well as get the global expansion business opportunity with various international academics, professionals, and CEOs of the global bio-health field!
BIO is where business and breakthroughs converge. Whether it’s across hemispheres or across the aisle, BIO brings the industry together to solve the most pressing issues facing our world. Attend innovative programming around therapeutic frontiers, policy, the business of biotech, regulatory updates, and the future of the biotech workforce.
The Redefining Early Stage Investments (RESI) conference series will come to Europe again connecting start-ups and early-stage investors and strategic channel partners. RESI maximizes fundraising companies’ efforts to find partners who are a fit for their technology and stage of development. RESI is uniquely cross-border and cross-domain, connecting start-ups with 10 categories of global investors across the silos of drugs, devices, diagnostics and digital health. RESI caters to both seed and angel capital, and the early-stage firms who seek series A and B funding. Biotechgate listed companies can use the following codes for a 10% discount:
- 1-day in person: BTGRESI1DAY
- 2-day virtual: BTGRESI2DAY
- 3-day: BTGRESI3DAY